Video

Simtra Biopharma Solutions Capacity Update April 2025: ADC

One of the most significant challenges in pharmaceutical manufacturing today is scaling complex, high-value injectable therapies while maintaining speed, quality, and regulatory compliance. As products like antibody-drug conjugates (ADCs) become more prevalent, the market faces increasing pressure to develop robust, scalable, and flexible processes.

Learn more about Simtra’s long-standing experience with ADCs and how they are expanding capacity and capabilities to meet evolving customer requirements for Antibody Drug Conjugates by watching the presentation below.

access the Video!

Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Outsourced Pharma? Subscribe today.

Subscribe to Outsourced Pharma X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Outsourced Pharma

Please tell us more about you so that we can customize our newsletters to your specific interests:

What topics interest you? (Check all that apply.)

Simtra BioPharma Solutions